EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 3.0

Evaluation of Pharmacokinetics and Safety of the Biosimilar (B01711) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study

Hui Liu iD, Haiyan Cao, Ting Li, Xinlei Chen, Hongling Yu, Jingfang Sun, Yerong Yu

Drug Design, Development and Therapy · 2025

DOI: 10.2147/dddt.s500347 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Hui Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu, Sichuan, People's Republic of China. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Hypoglycemic Agents, Insulin Aspart, Insulin, Long-Acting. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

B01711 is a biosimilar of insulin degludec/insulin aspart (IDegAsp 70/30). This randomized, open-label, single-dose, crossover, phase I study aimed to evaluate the pharmacokinetics (PK) and safety of B01711 compared to its original product (Ryzodeg) in healthy Chinese volunteers.

Methods

The study was conducted between April and August 2022, this study included 32 participants (22 males and 10 females) who received subcutaneous injections of both B01711 and Ryzodeg, with a ≥14-day washout period between treatments. All participants completed the study without any dropouts. Blood samples were collected at pre-defined intervals for PK analysis.

Results

The primary PK parameters included the area under the curve (AUC) of insulin degludec (IDeg) from 0 to 24 hours (AUCIDeg, 0-24 h), AUC of insulin aspart (IAsp) from 0 to the time of the last measurable value (AUCIAsp, 0-t), and the peak concentration of IAsp (CIAsp, max). PK equivalence would be established if the 90% confidence intervals (CIs) of least squares (LS) mean ratios of log-transformed values of primary PK endpoints for B01711 compared with Ryzodeg fell within the range of 80.0% to 125.0%. Safety was monitored throughout the study. The LS-mean ratios and corresponding 90% CIs were 106.1% (101.9%, 110.5%) for AUCIDeg, 0-24 h; 103.9% (100.2%, 107.6%) for AUCIAsp, 0-t; and 110.1% (101.0%, 119.9%) for CIAsp, max. Two treatment-emergent adverse events (TEAEs) were reported in two subjects (6.3%) in the B01711 group, and seven TEAEs were reported in seven subjects (21.9%) in the Ryzodeg group. The most common TEAE was a decrease in hemoglobin. The adverse events (AEs) of hypokalemia and hypoglycemia were identified as treatment-related AEs (TRAEs) and all TRAEs were mild.

Conclusion

This study demonstrated the PK equivalence of the two drugs and confirmed that both were well-tolerated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsHypoglycemic AgentsInsulin AspartInsulin, Long-ActingAdultFemaleHumansMaleYoung AdultArea Under CurveCross-Over StudiesDrug CombinationsHealthy VolunteersInjections, SubcutaneousEast Asian People

Stichwörter der Autor:innen

B01711IDegAspRyzodeghealthy subjectspharmacokineticsphase I study

Substanzen

Biosimilar PharmaceuticalsDrug CombinationsHypoglycemic AgentsInsulin Aspartinsulin degludec, insulin aspart drug combinationInsulin, Long-Acting

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu, Sichuan, People's Republic of China.
  • Clinical Trial Center, West China Hospital of Sichuan University, Chengdu, Sichuan, People's Republic of China.
  • Hui Sheng Bio-pharmaceutical Co., Ltd., Tonghua, Jilin, People's Republic of China.
  • Health Management Center, General Practice Medical Center, West China Hospital of Sichuan University, Chengdu, Sichuan, People's Republic of China.

ORCID-Profile: Hui Liu

Zitieren

APA

Liu, H., Cao, H., Li, T., Chen, X., Yu, H., Sun, J., & Yu, Y. (2025). Evaluation of Pharmacokinetics and Safety of the Biosimilar (B01711) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s500347

Vancouver

Liu H, Cao H, Li T, Chen X, Yu H, Sun J, et al. Evaluation of Pharmacokinetics and Safety of the Biosimilar (B01711) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s500347

BibTeX
@article{Liu2025,
  author = {Liu, Hui and Cao, Haiyan and Li, Ting and Chen, Xinlei and Yu, Hongling and Sun, Jingfang and Yu, Yerong},
  title = {Evaluation of Pharmacokinetics and Safety of the Biosimilar (B01711) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study},
  journal = {Drug Design, Development and Therapy},
  year = {2025},
  doi = {10.2147/dddt.s500347}
}
Kostenlos starten →